A Phase Ib, Open-Label, Randomized Study To Assess Safety And Preliminary Efficacy Of Tafasitamab (Mor208) Or Tafasitamab Plus Lenalidomide In Addition To R-Chop In Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis Of The Safety Run-In Phase